← Back to Clinical Trials
RecruitingNCT06135909

CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionPulmonary Hypertension
SponsorChinese Pulmonary Vascular Disease Research Group
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment5,000
SexALL
Min Age18 Years
Max Age85 Years
Start Date2020-01-01
Completion2027-12-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)

Eligibility Criteria

Inclusion Criteria: * Sign informed consent; * Between the ages of 18 and 85; * Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists). Exclusion Criteria: * Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study; * Patients with malignant tumor and other diseases and life expectancy of less than half a year; * Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology